Clinical trials located in

Cardiff

Cardiff city is located in United Kingdom. Currently, 20 clinical trials are being conducted in this city.

Cardiff, the capital city of Wales, boasts a rich history and vibrant culture. Established as a city in 1905 and as the capital in 1955, it is home to the iconic Cardiff Castle, a testament to its Roman and Norman past. The city is also famous for the Millennium Stadium, hosting significant sporting events. Cardiff Bay offers a stunning waterfront, revitalized from its industrial dockyard heritage. The city is a hub for media, being the location for BBC Wales and the filming of popular TV shows like Doctor Who. With its blend of historical landmarks and modern development, Cardiff stands as a dynamic urban center.

  • CT-EU-00119747

    Comparison of Olorofim and AmBisome® for Treating Invasive Aspergillosis in Patients Who Cannot Use Azole Therapy

    This study focuses on patients dealing with a serious fungal infection called Invasive Aspergillosis (IA). This infection is known to be particularly dangerous for people with weakened immune systems. Two drugs will be compared in this study: Olorofim (also known as F901318) and AmBisome® (liposomal amphotericin B). These drugs are used to treat patients who have a confirmed or suspected IA infection.

    AmBisome® is an established treatment, while Olorofim is a newer medication that works differently. This new drug aims to provide an alternative for patients who don’t respond well to existing therapies.

    The purpose of this study is to compare the effectiveness and safety of Olorofim with AmBisome®, followed by standard care according to medical guidelines. Patients will receive one of the treatments, and their response will be monitored over several months.

    Patients will start with either Olorofim or AmBisome® for a set period, then switch to the standard care recommended by their doctors. This approach allows researchers to understand how well each treatment works and what side effects might occur.

    Participation includes regular follow-ups and assessments to monitor the patient’s health, response to the medication, and any potential side effects. The ultimate goal is to find the best possible treatment for IA, improving outcomes for patients affected by this serious fungal infection.

    • AmBisome®
    • olorofim
  • Testing Vemurafenib and Cobimetinib for BRAF Positive Cancers

    This clinical trial is for patients with cancers that have a specific change in their cancer cells known as BRAF V600 mutation. It uses two drugs, vemurafenib and cobimetinib, to see if they can effectively treat various types of cancers such as solid tumors, haematological malignancies, melanoma, thyroid cancer, ovarian neoplasms, colorectal neoplasms, laryngeal neoplasms, non-small-cell lung carcinoma, glioma, multiple myeloma, and Erdheim-Chester disease. The purpose of this study is to determine if these drugs can help treat cancers with the BRAF V600 mutation.

    In the study, participants will receive both drugs until their disease progresses, they experience unacceptable side effects, or they decide to withdraw. Blood samples will be collected at different times during the treatment for research purposes. Participants will be monitored every three months for two years after completing the treatment.

    • Vemurafenib
    • Cobimetinib
  • Long-term safety and efficacy study of PTC518 for Huntington’s disease

    This study focuses on Huntington’s Disease and evaluates the long-term safety and effectiveness of the drug PTC518. Participants, who have previously completed related study phases, will continue taking PTC518 in doses of 5, 10, or 20 milligrams. The study aims to monitor the safety of long-term use and assess how the drug impacts biological markers and symptoms of the disease over a period of 30 months. This is an extension study where all participants will receive the active drug, ensuring continuous monitoring and evaluation of its effects.

    • PTC518
  • Study WVE-003 in patients with early-stage Huntington’s disease

    This clinical trial is a study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a new drug called WVE-003 in adult patients with early Huntington’s disease (HD). WVE-003 is a type of drug designed to target specific genetic sequences. In this case, it is targeting a single nucleotide polymorphism (SNP), known as SNP3, in Huntington’s disease patients. The drug is administered intrathecally, i.e., it is injected into the spinal canal.

    The study is double-blind, meaning neither patients nor researchers know who is receiving the actual drug and who is receiving the placebo. This helps ensure the results are impartial. The primary goal is to evaluate the safety of WVE-003 by monitoring the percentage of patients who experienced adverse events from day 1 to the end of the study, which lasts a minimum of 36 weeks.

    • WVE-003
  • A study on the safety and effectiveness of AMT-130 in the treatment of early Huntington’s disease in adults

    This clinical trial focuses on evaluating the safety and effectiveness of a new treatment called AMT-130 in adults with early symptoms of Huntington’s disease (HD). The goal is to collect data on the effectiveness of AMT-130 in sick patients.

    In the study, participants in Cohort 3 (Group 3) will receive either a high or low dose of AMT-130. Participants in this cohort will also receive immunosuppressive therapy consisting of dexamethasone, sirolimus, and rituximab. At the end of the month, 36 visit, participants will be informed about their assigned treatment group. The goal is to further evaluate the safety and effectiveness of low or high dose AMT-130.

    The study aims to expand the number of patients exposed to two doses to provide a sufficient sample for safety and effectiveness comparisons. The study will be conducted in approximately 5 to 8 European Huntington’s disease centers, 2 of which will serve as surgical centers. Both studies will share a common set of clinical, safety, imaging, and biomarker assessments over 5 years of follow-up.

    The main objectives of the study include assessing the safety and tolerability of administering AMT-130 to both hemispheres of the brain. This is a type of therapy that reduces the level of the HTT gene in adults with early symptoms of Huntington’s disease. The evaluation will include various parameters such as adverse events, changes in blood pressure, respiratory rate, heart rate, electrocardiograms, neurological and physical examinations, as well as laboratory tests such as clinical chemistry, hematology, urinalysis and cerebrospinal fluid analysis.

    • AMT-130
  • Study on SAGE-718 for improving cognitive function in Huntington’s disease

    This study focuses on Huntington’s Disease and aims to evaluate the effect of SAGE-718 on cognitive performance and functioning. Huntington’s Disease is a genetic disorder that affects the brain and leads to cognitive decline and motor dysfunction. The study will involve the drug SAGE-718 and a placebo. The primary goal is to understand how SAGE-718 impacts cognitive abilities in participants with Huntington’s Disease over 84 days. Participants will be randomly assigned to receive either the drug or a placebo daily, and their cognitive performance will be assessed using various tests.

    • SAGE-718
    • placebo
  • Study of Pembrolizumab/Quavonlimab Combination vs Other Treatments for Colorectal Cancer

    This here clinical trial is aimin’ to take a good look at a new combination treatment called co-formulated pembrolizumab/quavonlimab for folks with stage IV colorectal cancer that’s got that microsatellite instability-high or mismatch repair deficient business goin’ on. The main goal is to see how well this new combo treatment works at shrinkin’ them tumors, compared to some other treatments out there.

    Now, the real important part is that the doctors’ll be keepin’ a close eye on how many folks get what they call an objective response, meanin’ their tumors either disappear completely or shrink down by at least 30%. They’ll be trackin’ this over a span of up to around 50 months to get a good picture of how effective this new treatment is.

    Safety’s always a top priority too, so the doctors’ll be watchin’ out for any side effects or issues that might crop up with this new combo treatment. It’s all about findin’ the best way to fight that cancer while keepin’ folks as comfortable as possible.

  • Study of a new anticancer vaccine (SCIB1) in combination with immunotherapeutic drugs in the treatment of malignant melanoma

    The aim of this clinical trial is to test whether a new cancer vaccine called SCIB1 can be safely used with two approved treatments for advanced melanoma – nivolumab (Opdivo) plus ipilimumab (Yervoy) or pembrolizumab (Keytruda). The study will also examine whether adding SCIB1 to these therapies can increase the chances of melanoma responding to treatment and the duration of that response.

    Currently, SCIB1 is still considered experimental, but has been previously administered to melanoma patients and was well tolerated. Scientists have even seen some signs that it may help stimulate the immune system to fight cancer. In this study, SCIB1 will be administered up to 10 times over 85 weeks by injection into the arm or leg using a special needle-free device. Before starting treatment, you will undergo several screening tests to make sure you are eligible to take part.

    • SCIB1 DNA vaccine
  • Comparing ruxolitinib, hydroxycarbamide, and Interferon as first-line treatments for high-risk Polycythemia Vera

    The study, known as MITHRIDATE, investigates the effectiveness of the drug Ruxolitinib compared to either Hydroxycarbamide or Interferon Alpha for patients with high-risk Polycythemia Vera, a type of blood disorder. This Phase III clinical trial aims to determine which treatment is more effective in managing the disease without leading to additional health complications.

    Patients in the trial are assigned to receive either Ruxolitinib or the best available therapy, chosen from Hydroxycarbamide or Interferon Alpha, as decided by the overseeing doctors. The course of the study involves regular monitoring and assessments to evaluate the impact of these treatments on the disease’s progression and patients’ overall health and quality of life. The study is conducted in a controlled environment to ensure reliable results.

    • Interferon-Alpha
    • Hydroxycarbamide
    • Ruxolitinib
  • Study on INCB000928 Alone or With Ruxolitinib for Anemia in Myeloproliferative Disorders

    This clinical trial is designed to explore the effects of a new medication called INCB000928, either on its own or when used together with another drug known as ruxolitinib. The main goal is to see how safe and tolerable this treatment is for individuals suffering from anemia due to certain myeloproliferative disorders, including conditions like post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis. These are types of blood disorders that can lead to symptoms such as fatigue due to anemia.

    The study is divided into two parts: the first part will focus on finding the right dose of the medication, and the second part will expand on these findings to further understand the treatment’s effects. Participants in this study will be closely monitored to assess any side effects and to see how well the treatment is working, with a particular focus on how it impacts anemia and the need for blood transfusions.

    This research is being conducted in an open-label which means both the researchers and participants will know which treatment is being administered. The safety, tolerability, and effectiveness of INCB000928, both as a standalone therapy and in combination with ruxolitinib, will be evaluated over approximately 13 months. This study represents an important step towards finding new treatments for those dealing with the challenges of anemia due to myeloproliferative disorders.

    • Ruxolitinib
    • INCB000928
  • Comparison of zibotentan/dapagliflozin with dapagliflozin alone in the treatment of chronic kidney disease with high proteinuria

    The study aims to understand how to better treat people with chronic kidney disease (CKD) and high proteinuria. This study is in its third phase and involves multiple centers where participants will be closely monitored. The main goal is to compare the effectiveness, safety, and how well participants tolerate a combination treatment of zibotentan/dapagliflozin versus dapagliflozin alone.

    During this study, participants will be randomly assigned to one of two groups. One group will receive the combination of zibotentan and dapagliflozin, while the other group will receive only dapagliflozin. Both treatments aim to slow down the decline in kidney function, which is a major concern for people with CKD and high proteinuria. The key measure of success for this study is the change in eGFR from baseline, which is a test used to check how well the kidneys are working, specifically by measuring the estimated glomerular filtration rate (eGFR). This will be assessed at the 24-month mark of the study.

    This research is crucial because it could lead to better treatment options for those suffering from CKD and high proteinuria, potentially improving their quality of life and health outcomes.

    • Zibotentan/Dapagliflozin
    • Dapagliflozin
  • SPI-62 as new drug for patients with ACTH-dependent Cushing’s syndrome

    This is a study focused on a new treatment option, SPI-62, for people struggling with ACTH-independent Cushing’s Syndrome. The main aim is to evaluate the efficacy and safety of SPI-62 in treating the condition.

    SPI-62 is a drug that works by inhibiting a specific enzyme in the body, potentially reducing excessive cortisol levels that contribute to the disease. During this study, participants will receive SPI-62 in oral tablet form. Dosing will vary, starting at a lower dose and potentially increasing depending on patient response and study requirements.

    The study has been designed as a Phase 2 trial, meaning that the primary focus is on understanding how well SPI-62 can treat the symptoms of hypercortisolism and what its safety profile is. Participants will be in the study for an extended period of time, with scheduled visits at baseline and then at 1, 3, 6, 9 and 12 months, followed by quarterly visits. These visits are crucial to monitor health status and treatment impact.

    One of the key aspects the researchers will be looking at is the change in HbA1c levels, a marker of blood sugar control, after both 6 and 12 weeks of treatment. This will help to understand whether SPI-62 can improve diabetes or the impaired glucose tolerance that often accompanies diabetes.

    • SPI-62- new potential medication for Cushing’s syndrome and Autonomous Cortisol Secretion
  • Examining capivasertib and docetaxel in advanced prostate cancer

    This trial is testing a new potential treatment for a type of advanced prostate cancer. The study will compare two combinations: one with Capivasertib and another called Docetaxel, compared with placebo (a dummy tablet with no medical effect) and Docetaxel. In addition, each study participant will receive steroid treatment and another therapy called androgen deprivation therapy. The main goal of this study is to demonstrate whether Capivasertib + Docetaxel extends patients’ lives more than placebo + Docetaxel. They will also be monitored for the time it takes for the cancer to show signs of growth again, for the pain to increase or for urinary symptoms to worsen.

    • Capivasertib
    • Docetaxel
  • Stomach cancer treatment comparison: trastuzumab deruxtecan vs. ramucirumab & paclitaxel

    This is a thorough comparison study to measure the effectiveness and safety of two treatment paths. It’s designed for individuals who have experienced progression regarding a stomach (gastric) cancer, or cancer of the gastro-esophageal junction (GEJ). The study focuses on those with HER2-positive gastric or GEJ who have previously undergone a trastuzumab-containing regime but have not received further systemic therapy.The research compares the use of trastuzumab deruxtecan, a potent anti-cancer agent, and the combined use of ramucirumab and paclitaxel. The study’s primary goal is to evaluate the overall survival rate, while secondary aims involve examining progression-free survival, response duration, disease control, safety, pharmacokinetics, and immunogenicity.In the study, participants are fairly and randomly assigned to receive one of two treatments. This is crucial in understanding the superiority and safety of these treatment paths, and this knowledge may inform future approaches to treating these types of cancer.

    • Ramucirumab
    • Trastuzumab deruxtecan
    • Paclitaxel
  • Studying the new drug AZD8205 as a potential treatment for advanced or metastatic solid tumors

    The clinical trial is aimed at patients with advanced or metastatic solid tumors. It applies to various types of cancer, such as breast cancer, bile duct cancer, ovarian cancer and endometrial cancer.

    The study is evaluating a new compound called AZD8205, both alone and in combination with other anticancer drugs. AZD8205 is a drug-antibody conjugate, which means that the drug is linked to it. This combination helps deliver the drug directly to the cancer cells. AZD8205 will be used in combination with the drug rilvegostomig. Rilvegostomig is a biospecific antibody that binds to two different proteins (TIGIT and PD-1), which may help in the treatment of advanced solid tumors.

    The aim of the study is to assess the safety and tolerability of AZD8205 and to determine how effective it is against selected cancers. Patients will be monitored for side effects and their body’s response to treatment to help determine the best dosage and determine the maximum tolerated dose.

    The trial is open to adult patients with certain types of cancer who meet eligibility criteria. Researchers will evaluate both the positive and negative effects of the drug to find out whether it is suitable for treating these specific types of cancer.

    • AZD8205- new potential medication for solid tumors
  • Study of trastuzumab deruxtecan in gastric cancer or gastroesophageal junction adenocarcinoma

    The aim of the DESTINY-Gastric04 study is to help cancer patients suffering from certain diseases. These patients have a specific type of stomach cancer or adenocarcinoma of the gastroesophageal junction that has not responded to treatment or has gotten worse after treatment with a medicine called trastuzumab. This study is testing a new drug called trastuzumab deruxtecan, comparing it with a combination of two other drugs – ramucirumab and paclitaxel. A key goal of this study is to determine how long participants will live after starting a new treatment. It will also be observed whether the cancer will shrink or stop growing, how long it will last, what the potential side effects of treatment will be and how the body will respond to the new drug.

    • Ramucirumab
    • Trastuzumab deruxtecan
    • Paclitaxel
  • Testing new medication for safety and effect on Huntington’s disease

    This study focuses on Huntington’s Disease and evaluates the safety and effectiveness of the drug PTC518. Participants will be randomly assigned to different groups based on their disease stage and will receive either PTC518 in varying doses (5 mg, 10 mg, or 20 mg) or a placebo. The study’s main aim is to observe the drug’s safety and its effects on disease-related proteins and brain changes over 12 months.

    • PTC518- new potential medication for Huntington’s disease
  • Testing new combination treatments for kidney cancer

    This study, part of a broader research project exploring new treatments for kidney cancer, specifically Renal Cell Carcinoma (RCC). These treatments include different combinations of drugs from among the listed: Pembrolizumab, Favezelimab, Belzutifan, Lenvatinib, Quavonlimab and Vibostolimab. The research comprises two stages: a safety assessment stage and an efficacy evaluation stage. In the first stage, the study aims to determine the safety and tolerability of a few different drug combinations. The study will monitor any unexpected adverse health events and track the number of participants who may need to discontinue the treatment due to health concerns. In the second stage, the study will assess the effectiveness of these various drug combinations and identify any uncomfortable or unwelcome effects. Additionally, researchers will observe how many participants can continue the treatment without experiencing adverse effects.

    • Vibostolimab
    • Quavonlimab
    • Pembrolizumab
    • Favezelimab
    • Lenvatinib
    • Belzutifan
  • Medicine combination study for various advanced cancers

    This trial explores the effects of a two-drug combo on various advanced cancers, focusing on the best tolerable doses. Adults with advanced solid tumors, like lung cancer, gastric cancer, and sarcoma, are included. The trial involves the drugs BI 907828 and ezabenlimab, aiming to shrink tumors. Participants receive treatments in cycles, with regular health checks to assess benefits and monitor side effects. When the study began, some participants were given an extra medicine called BI 754111. However, the use of BI 754111 was discontinued because data from another study revealed that it did not provide any additional benefits. The study seeks to offer new hope for those facing advanced cancers by testing this novel treatment approach.

    • Miptenalimab/BI-754111
    • Brigimadlin/BI 907828
    • ezabenlimab
  • Testing new treatment for rare genetic disorder X-linked hypohidrotic ectodermal dysplasia

    This research is about trying a new treatment for unborn boys who are known to have a disease called X-linked Hypohidrotic Ectodermal Dysplasia (XLHED). XLHED is a rare condition that affects parts of the body such as sweat glands, teeth, and hair. The reason this happens is due to errors in a certain gene. This leads to various problems like not being able to sweat properly, missing teeth, and not having normal hair growth. The tested treatment, called ER004, is meant to replace a missing protein that’s caused by these errors. The aim is to prevent the disease in the babies. There will be a long observational period for the boys after birth, up to 5 years, where doctors will check if the treatment is safe and effective. This includes their ability to sweat, the development of teeth, and overall health. Doctors will also compare these signs with the ones of boys who did not get the treatment or from a previous study. The health of the mothers after delivery will also be checked.

    • ER004

See more clinical trials in other cities in United Kingdom:

.